Market research
TLT.V Theralase Technologies Inc
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 57M
- P/E ratio
- Not available
- Analyst target
- 0.7
- Dividend yield
- Not available
- Beta
- 0.49
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- CA88337V1004
- Market cap
- 57M
- P/E ratio
- Not available
- Analyst target
- 0.7
- Dividend yield
- Not available
- Beta
- 0.49
About
About Theralase Technologies Inc
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TLT.V discussion.
5 years, 5 months ago
Theralase Technologies Inc is currently in a long term uptrend where the price is trading 8.1% above its 200 day moving average.
From a valuation standpoint, the stock is 95.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 48.6.
Theralase Technologies Inc's total revenue rose by 62.0% to $234K since the same quarter in the previous year.
Its net income has increased by 19.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.8% to $-806K since the same quarter in the previous year.
Based on the above factors, Theralase Technologies Inc gets an overall score of 5/5.